news
New Lancet correspondence questions clinical meaning of Alzheimer's amyloid drugs
A new correspondence in The Lancet argues that while amyloid-beta antibodies like lecanemab and donanemab do clear amyloid from the brain, their clinical benefit for Alzheimer's patients isn't "meaningful." Researchers point to pooled data from multiple trials showing little real-world improvement for individuals. It's a direct challenge to the approved drugs.
A new correspondence in The Lancet argues that while amyloid-beta antibodies like lecanemab and donanemab do clear amyloid from the brain, their clinical benefit for Alzheimer's patients isn't "meaningful." Researchers point to pooled data from multiple trials showing little real-world improvement for individuals. It's a direct challenge to the approved drugs.
The architecture take
I've been watching this space, and this new correspondence from The Lancet cuts straight to the core issue with Alzheimer's amyloid-clearing drugs: is clearing amyloid really helping people? The drugs do what they say they'll do on a biomarker level – they sweep out beta-amyloid proteins from the brain. That's a win for the mechanism, sure. But the argument here is that the clinical impact, the actual felt difference for someone living with Alzheimer's, is too small to call 'meaningful.' This isn't just one study; it's a look at pooled data, suggesting a pattern. It reminds me that a lab success doesn't always translate to a human experience. What good is a 'cleaner' brain if memory and function don't tangibly improve? This pushes the conversation back to what truly impacts brain aging and cognition in our day-to-day lives.